Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12841233 | 1.00 | OPRK1 (0.36) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL18197338 | 0.93 | ALK (0.36) | KDM4ETDP1BACE1APPPPARG | |
| SCHEMBL2637772 | 0.93 | OPRK1 (0.35) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL20175916 | 0.93 | MAPT (0.34) | KDM4ETDP1HSP90AA1APPPPARG | |
| SCHEMBL1534182 | 0.91 | OPRK1 (0.35) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL30662548 | 0.91 | OPRK1 (0.35) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL1534231 | 0.91 | OPRK1 (0.35) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL12850782 | 0.91 | OPRK1 (0.35) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL11963439 | 0.91 | SLC22A12 (0.37) | OPRK1KDM4ETDP1CHEK1BACE1 | |
| SCHEMBL11963323 | 0.91 | SLC22A12 (0.37) | OPRK1KDM4ETDP1CHEK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105078-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| EP-2790697-B1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIV FLORIDA (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20170209420-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209420-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20140343110-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343110-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2013090750-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013086312-A1 | ORAL FORMULATIONS FOR TREATING METAL OVERLOAD | FERROKIN BIOSCIENCES, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105078-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | TFRC, AIFM2, VIP | OPRK1 825/4885KDM4E 4566/4885TDP1 3727/4885 |
| US-20140343110-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | TFRC, AIFM2, VIP | OPRK1 792/4885KDM4E 4686/4885TDP1 3827/4885 |
| US-20170209420-A1 | USES OF 4'-DESFERRITHIOCIN ANALOGS | TFRC, AIFM2, VIP | OPRK1 792/4885KDM4E 4686/4885TDP1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.